RxDoctor Payments DataLook up a doctor →

Dana Carter

Nurse Practitioner · Murfreesboro, TNNPI 1215273917

Payments from drug & device makers

$31,299in general payments, 2019–2025

Across 1,146 payments — averaging $27.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$6K
  • EMD Serono, Inc.$5K
  • AbbVie$2K
  • AstraZeneca$2K
  • UCB, Inc.$1K
  • Novartis$1K
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$6162%
  • Speaking & faculty fees$4,84315%
  • Food & beverage$25,39781%
  • Education$4431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen77$5,650
EMD Serono, Inc.77$5,365
AbbVie(2 entities)106$2,350
AstraZeneca(2 entities)49$1,760
UCB, Inc.53$1,483
Novartis56$1,152
ANI Pharmaceuticals, Inc.56$1,084
SK Life Science, Inc.48$1,005
Teva Pharmaceuticals USA, Inc.100$972
Biohaven Pharmaceuticals, Inc.43$714
Pfizer40$609
Sanofi12$585
TG Therapeutics, Inc.24$569
Neurocrine Biosciences, Inc.21$500
MDD US Operations, LLC8$436
Johnson & Johnson(2 entities)22$415
Genentech USA, Inc.21$415
Biohaven Pharmaceutical Holding Company Ltd.33$409
Impel Pharmaceuticals Inc.14$359
Neurelis, Inc.20$354
Lundbeck LLC19$332
Lilly USA, LLC20$299
Upsher-smith Laboratories LLC27$295
Amgen(2 entities)13$290
Axsome Therapeutics, Inc.13$287
Acadia Pharmaceuticals Inc15$278
Bristol Myers Squibb13$224
Genentech, Inc.2$214
Eisai Inc.9$147
Alnylam Pharmaceuticals Inc.5$121
Abbott2$120
Mallinckrodt Hospital Products Inc.6$118
Sumitomo Pharma America, Inc.6$110
Supernus Pharmaceuticals, Inc.2$106
Sunovion Pharmaceuticals Inc.9$100
Otsuka America Pharmaceutical, Inc.5$96
Argenx US, Inc.5$95
Averitas Pharma Inc.3$95
Grifols USA, LLC5$91
Kyowa Kirin, Inc.5$89
Jazz Pharmaceuticals Inc.3$83
Banner Life Sciences, LLC4$81
Cycle Pharmaceuticals Inc4$81
CSL Behring3$77
Amneal Pharmaceuticals LLC5$77
Corcept Therapeutics4$73
Dexcom, Inc.4$72
Scilex Pharmaceuticals Inc.3$68
Takeda Pharmaceuticals U.S.A., Inc.2$61
Novo Nordisk3$56
Insulet Corporation3$54
Catalyst Pharmaceuticals, Inc.2$50
Inspire Medical Systems, Inc.2$47
Merz Pharmaceuticals, LLC2$40
Cequr Corporation2$38
Adamas Pharmaceuticals, Inc.2$37
Ascendis Pharma Endocrinology Inc2$36
IBSA Pharma Inc.2$30
Clarus Therapeutics Inc.2$29
Ultragenyx Pharmaceutical Inc.1$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,299 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$42,512
Medicare patients
228
Services billed
629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab36$413,667
OcrevusOcrelizumab11$388,902
BivigamImmun Glob G(Igg)/Gly/Iga Ov5034$379,092
TysabriNatalizumab26$217,170
IngrezzaValbenazine Tosylate15$136,824
Nurtec OdtRimegepant Sulfate63$131,206
ZeposiaOzanimod Hydrochloride11$97,788
UbrelvyUbrogepant64$82,505
Aimovig AutoinjectorErenumab-Aooe81$80,187
NuplazidPimavanserin Tartrate15$75,204
BriviactBrivaracetam43$53,452
QuliptaAtogepant48$51,852
XcopriCenobamate27$50,939
NuedextaDextromethorphan Hbr/Quinidine18$18,651
Dalfampridine ErDalfampridine33$15,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Ocrevus$214$388,90211 claims
BiogenTysabri$5,650$217,17026 claims
Neurocrine Biosciences, Inc.Ingrezza$500$136,82415 claims
AbbVieUbrelvy, Qulipta$2,350$134,357112 claims
PfizerNurtec Odt$609$131,20663 claims
Acadia Pharmaceuticals IncNuplazid$278$75,20415 claims
UCB, Inc.Briviact$1,483$53,45243 claims
SK Life Science, Inc.Xcopri$1,005$50,93927 claims
Upsher-smith Laboratories LLCTopiramate$295$2,604166 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →